Chikungunya

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:324625A92.0
Who is this for?
Show terms as
12Active trials37Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Chikungunya is an infectious disease caused by the chikungunya virus, which is spread to people through the bite of infected mosquitoes, mainly Aedes aegypti and Aedes albopictus. The name comes from a word in the Kimakonde language meaning "to become contorted," referring to the stooped posture people develop from severe joint pain. The disease typically begins suddenly with high fever and intense joint pain, usually affecting the hands, wrists, ankles, and feet on both sides of the body. Other common symptoms include headache, muscle pain, joint swelling, and a skin rash. Most people start feeling sick 4 to 8 days after being bitten by an infected mosquito. While chikungunya is rarely fatal, the joint pain can be extremely severe and debilitating, sometimes lasting for weeks, months, or even years after the initial infection. This chronic joint pain is one of the most challenging aspects of the disease and can significantly affect quality of life. Newborns infected around the time of birth and older adults with other health conditions are at higher risk for severe disease. There is currently no specific antiviral treatment for chikungunya. Care focuses on relieving symptoms with rest, fluids, and pain medications such as acetaminophen. In late 2023, the FDA approved the first chikungunya vaccine, Ixchiq (VLA1553), for adults aged 18 and older who are at increased risk of exposure. This was a major milestone in prevention. Research continues into antiviral therapies and additional vaccines.

Key symptoms:

High fever (often above 102°F/39°C)Severe joint pain, especially in hands, wrists, ankles, and feetJoint swellingMuscle painHeadacheSkin rash (often appearing a few days after fever)Fatigue and weaknessNauseaBack painEye pain or sensitivity to lightChronic joint pain lasting months or yearsJoint stiffness, especially in the morningLoss of appetiteSwollen lymph nodes

Clinical phenotype terms (50)— hover any for plain English
Abnormal diminished volitionHP:0000745Stiff interphalangeal jointsHP:0005198Depigmentation/hyperpigmentation of skinHP:0007483Shoulder painHP:0030834Knee painHP:0030839Maculopapular exanthemaHP:0040186
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Aug 2026A Phase I Study of PepGNP-ChikV in Healthy Volunteers

Gylden Pharma Ltd — EARLY_PHASE1

TrialNOT YET RECRUITING
May 2026An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults

Bavarian Nordic — PHASE3

TrialNOT YET RECRUITING
Apr 2026Against Chikungunya Virus and Neonatal Infection

Centre Hospitalier Universitaire de la Réunion — NA

TrialNOT YET RECRUITING
Mar 2026Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.

Butantan Institute — PHASE3

TrialNOT YET RECRUITING
Mar 2026VLA1553-403 Pregnancy Surveillance Study

Valneva Austria GmbH

TrialNOT YET RECRUITING
Feb 2026Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

Valneva Austria GmbH

TrialENROLLING BY INVITATION
Feb 2026Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil

Valneva Austria GmbH

TrialENROLLING BY INVITATION
Sep 2025Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

Valneva Austria GmbH

TrialACTIVE NOT RECRUITING
Sep 2025Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections

Hospital Israelita Albert Einstein

TrialNOT YET RECRUITING
Aug 2025A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever

Jiangsu Kanion Pharmaceutical Co., Ltd — NA

TrialNOT YET RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Chikungunya.

12 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

12 recruitingView all trials with filters →
Phase 34 trials
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
Phase 3
Active
PI: Patrick Ajiboye, MD (Bavarian Nordic) · Sites: Mobile, Alabama; Tempe, Arizona +22 more · Age: 1299 yrs
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
Phase 3
Actively Recruiting
PI: Patrick Ajiboye, MD (Bavarian Nordic A/S) · Sites: Fountain Valley, California; Washington D.C., District of Columbia +13 more · Age: 111 yrs
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
Phase 3
Active
PI: Valneva Clinical Development (Valneva Austria GmbH) · Sites: Phoenix, Arizona; Hallandale, Florida +8 more · Age: 1899 yrs
Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH)
Phase 3
Active
· Sites: Barranquilla · Age: 1899 yrs
Phase 41 trial
Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion
Phase 4
Actively Recruiting
PI: Patrick GERARDIN, MD (CHU La Réunion) · Sites: Saint-Denis · Age: 1899 yrs
N/A1 trial
Virological and Immunological Determinants of Arbovirus Infection in New Caledonia
N/A
Actively Recruiting
PI: Myrielle Dupont-Rouzeyrol, PhD (Institut Pasteur de Nouvelle-Calédonie) · Sites: Dumbéa Sur Mer · Age: 1899 yrs
Other6 trials
Real-World Study on Chinese Medicine for Treating Chikungunya Fever
Actively Recruiting
· Sites: Guangzhou, Guangdong
The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers
Active
· Sites: Strasbourg · Age: 1899 yrs
Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil
Enrolling by Invitation
· Sites: Fortaleza, Ceará; Belo Horizonte, Minas Gerais +2 more · Age: 1859 yrs
Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
Active
· Sites: Fortaleza, Ceará; Belo Horizonte, Minas Gerais +2 more · Age: 299 yrs
Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
Enrolling by Invitation
· Sites: Fortaleza, Ceará; Belo Horizonte, Minas Gerais +2 more · Age: 1899 yrs
Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
Actively Recruiting
PI: Myrielle Dupont-Rouzeyrol, PhD (Institut Pasteur de Nouvelle-Calédonie) · Sites: Dumbéa Sur Mer, Nouvelle-Calédonie · Age: 299 yrs

Specialists

Showing 25 of 37View all specialists →
BM
Bruno Hoen, MD
Specialist
PI on 1 active trial
PM
Patrick Ajiboye, MD
MERIDIAN, MS
Specialist
PI on 5 active trials
CM
Clemente Diaz, MD
RICHWOOD, WV
Specialist
PI on 3 active trials
PA
Patrick Ajiboye
MERIDIAN, MS
Specialist
PI on 1 active trial
YM
Yeycy Donastorg, MD
Specialist
PI on 1 active trial
NM
Nicolas Rosario, MD
BRONX, NY
Specialist
PI on 1 active trial
AM
Andre Cabie, MD
Specialist
PI on 3 active trials1 Chikungunya publication
MP
Myrielle Dupont-Rouzeyrol, PhD
Specialist
PI on 4 active trials
JM
James McCarty, MD
Specialist
PI on 5 active trials
MM
Matthew J Memoli, M.D.
BETHESDA, MD
Specialist
PI on 6 active trials
JM
Jean W Pape, MD
Specialist
PI on 2 active trials
CP
Cameron Simmons, Prof.
Specialist
PI on 1 active trial
LM
Luiz F Oliveira, M.D.
Specialist
PI on 1 active trial
RD
Rocio Cardenas, Research Dr.
Specialist
PI on 1 active trial
AM
Aileen Y Chang, MD MSPH
Specialist
PI on 1 active trial
AD
Axel Kroeger, Prof. Dr.
Specialist
PI on 1 active trial
SS
Sushant Sahastrabuddhe
Specialist
PI on 1 active trial
SS
Sophia Siddiqui
BETHESDA, MD
Specialist
PI on 1 active trial
JL
Julie E Ledgerwood
BETHESDA, MD
Specialist
PI on 3 active trials
KM
Krishna Mohan
CINCINNATI, OH
Specialist
PI on 1 active trial
CY
Christina Yek
BETHESDA, MD
Specialist
PI on 1 active trial
AU
Adi Utarini
Specialist
PI on 1 active trial
PG
Patrick GERARDIN
Specialist
PI on 1 active trial
RK
Renata N Kirkwood
Specialist
PI on 1 active trial
RS
Raphaelle SARTON
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Chikungunya.

Search all travel grants →NORD Financial Assistance ↗

Community

Open ChikungunyaForum →

No community posts yet. Be the first to share your experience with Chikungunya.

Start the conversation →

Latest news about Chikungunya

Disease timeline:

New recruiting trial: Real-World Study on Chinese Medicine for Treating Chikungunya Fever

A new clinical trial is recruiting patients for Chikungunya

New recruiting trial: Virological and Immunological Determinants of Arbovirus Infection in New Caledonia

A new clinical trial is recruiting patients for Chikungunya

New recruiting trial: A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

A new clinical trial is recruiting patients for Chikungunya

New recruiting trial: Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia

A new clinical trial is recruiting patients for Chikungunya

New recruiting trial: Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion

A new clinical trial is recruiting patients for Chikungunya

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How can I tell if my symptoms are from chikungunya and not dengue or Zika?,What pain medications are safe for me to take right now?,How long should I expect my joint pain to last, and what are the chances it becomes chronic?,What can I do to prevent spreading the virus to my family members?,Should I see a rheumatologist if my joint pain continues after the fever goes away?,Are there any warning signs I should watch for that would require emergency care?,Is the chikungunya vaccine recommended for me or my family members for future protection?

Common questions about Chikungunya

What is Chikungunya?

Chikungunya is an infectious disease caused by the chikungunya virus, which is spread to people through the bite of infected mosquitoes, mainly Aedes aegypti and Aedes albopictus. The name comes from a word in the Kimakonde language meaning "to become contorted," referring to the stooped posture people develop from severe joint pain. The disease typically begins suddenly with high fever and intense joint pain, usually affecting the hands, wrists, ankles, and feet on both sides of the body. Other common symptoms include headache, muscle pain, joint swelling, and a skin rash. Most people start f

How is Chikungunya inherited?

Chikungunya follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Chikungunya?

Yes — 12 recruiting clinical trials are currently listed for Chikungunya on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Chikungunya?

25 specialists and care centers treating Chikungunya are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.